393 related articles for article (PubMed ID: 30277471)
1. CD84 regulates PD-1/PD-L1 expression and function in chronic lymphocytic leukemia.
Lewinsky H; Barak AF; Huber V; Kramer MP; Radomir L; Sever L; Orr I; Mirkin V; Dezorella N; Shapiro M; Cohen Y; Shvidel L; Seiffert M; Herishanu Y; Becker-Herman S; Shachar I
J Clin Invest; 2018 Dec; 128(12):5465-5478. PubMed ID: 30277471
[TBL] [Abstract][Full Text] [Related]
2. CD84 is a regulator of the immunosuppressive microenvironment in multiple myeloma.
Lewinsky H; Gunes EG; David K; Radomir L; Kramer MP; Pellegrino B; Perpinial M; Chen J; He TF; Mansour AG; Teng KY; Bhattacharya S; Caserta E; Troadec E; Lee P; Feng M; Keats J; Krishnan A; Rosenzweig M; Yu J; Caligiuri MA; Cohen Y; Shevetz O; Becker-Herman S; Pichiorri F; Rosen S; Shachar I
JCI Insight; 2021 Feb; 6(4):. PubMed ID: 33465053
[TBL] [Abstract][Full Text] [Related]
3. Control of PD-L1 expression in CLL-cells by stromal triggering of the Notch-c-Myc-EZH2 oncogenic signaling axis.
Böttcher M; Bruns H; Völkl S; Lu J; Chartomatsidou E; Papakonstantinou N; Mentz K; Büttner-Herold M; Zenz T; Herling M; Huber W; Ghia P; Stamatopoulos K; Mackensen A; Mougiakakos D
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33931470
[TBL] [Abstract][Full Text] [Related]
4. PD-L1 checkpoint blockade prevents immune dysfunction and leukemia development in a mouse model of chronic lymphocytic leukemia.
McClanahan F; Hanna B; Miller S; Clear AJ; Lichter P; Gribben JG; Seiffert M
Blood; 2015 Jul; 126(2):203-11. PubMed ID: 25800048
[TBL] [Abstract][Full Text] [Related]
5. CD84 mediates CLL-microenvironment interactions.
Marom A; Barak AF; Kramer MP; Lewinsky H; Binsky-Ehrenreich I; Cohen S; Tsitsou-Kampeli A; Kalchenko V; Kuznetsov Y; Mirkin V; Dezorella N; Shapiro M; Schwartzberg PL; Cohen Y; Shvidel L; Haran M; Becker-Herman S; Herishanu Y; Shachar I
Oncogene; 2017 Feb; 36(5):628-638. PubMed ID: 27452524
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms of PD-L1/PD-1-mediated CD8 T-cell dysfunction in the context of aging-related immune defects in the Eµ-TCL1 CLL mouse model.
McClanahan F; Riches JC; Miller S; Day WP; Kotsiou E; Neuberg D; Croce CM; Capasso M; Gribben JG
Blood; 2015 Jul; 126(2):212-21. PubMed ID: 25979947
[TBL] [Abstract][Full Text] [Related]
7. Chronic lymphocytic leukaemia induces an exhausted T cell phenotype in the TCL1 transgenic mouse model.
Gassner FJ; Zaborsky N; Catakovic K; Rebhandl S; Huemer M; Egle A; Hartmann TN; Greil R; Geisberger R
Br J Haematol; 2015 Aug; 170(4):515-22. PubMed ID: 25940792
[TBL] [Abstract][Full Text] [Related]
8. PD-1 Expression in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Large B-cell Richter Transformation (DLBCL-RT): A Characteristic Feature of DLBCL-RT and Potential Surrogate Marker for Clonal Relatedness.
He R; Ding W; Viswanatha DS; Chen D; Shi M; Van Dyke D; Tian S; Dao LN; Parikh SA; Shanafelt TD; Call TG; Ansell SM; Leis JF; Mai M; Hanson CA; Rech KL
Am J Surg Pathol; 2018 Jul; 42(7):843-854. PubMed ID: 29762141
[TBL] [Abstract][Full Text] [Related]
9. CD84 is a Suppressor of T and B Cell Activation during Mycobacterium tuberculosis Pathogenesis.
Zheng N; Fleming J; Hu P; Jiao J; Zhang G; Yang R; Li C; Liu Y; Bi L; Zhang H
Microbiol Spectr; 2022 Feb; 10(1):e0155721. PubMed ID: 35196822
[TBL] [Abstract][Full Text] [Related]
10. PD-1 and PD-L1 gene expressions and their association with Epstein-Barr virus infection in chronic lymphocytic leukemia.
Gamaleldin MA; Ghallab OM; Nadwan EA; Abo Elwafa RA
Clin Transl Oncol; 2021 Nov; 23(11):2309-2322. PubMed ID: 34120295
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-10 suppression enhances T-cell antitumor immunity and responses to checkpoint blockade in chronic lymphocytic leukemia.
Rivas JR; Liu Y; Alhakeem SS; Eckenrode JM; Marti F; Collard JP; Zhang Y; Shaaban KA; Muthusamy N; Hildebrandt GC; Fleischman RA; Chen L; Thorson JS; Leggas M; Bondada S
Leukemia; 2021 Nov; 35(11):3188-3200. PubMed ID: 33731852
[TBL] [Abstract][Full Text] [Related]
12. Expression of Programmed Death 1 Ligand in Different Compartments of Chronic Lymphocytic Leukemia.
Grzywnowicz M; Karczmarczyk A; Skorka K; Zajac M; Zaleska J; Chocholska S; Tomczak W; Giannopoulos K
Acta Haematol; 2015; 134(4):255-62. PubMed ID: 26159545
[TBL] [Abstract][Full Text] [Related]
13. CD84 is a survival receptor for CLL cells.
Binsky-Ehrenreich I; Marom A; Sobotta MC; Shvidel L; Berrebi A; Hazan-Halevy I; Kay S; Aloshin A; Sagi I; Goldenberg DM; Leng L; Bucala R; Herishanu Y; Haran M; Shachar I
Oncogene; 2014 Feb; 33(8):1006-16. PubMed ID: 23435417
[TBL] [Abstract][Full Text] [Related]
14. The PD-1/PD-L1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia.
Brusa D; Serra S; Coscia M; Rossi D; D'Arena G; Laurenti L; Jaksic O; Fedele G; Inghirami G; Gaidano G; Malavasi F; Deaglio S
Haematologica; 2013 Jun; 98(6):953-63. PubMed ID: 23300177
[TBL] [Abstract][Full Text] [Related]
15. What does PD-L1 positive or negative mean?
Ribas A; Hu-Lieskovan S
J Exp Med; 2016 Dec; 213(13):2835-2840. PubMed ID: 27903604
[TBL] [Abstract][Full Text] [Related]
16. Programmed death-1 and its ligand are novel immunotolerant molecules expressed on leukemic B cells in chronic lymphocytic leukemia.
Grzywnowicz M; Zaleska J; Mertens D; Tomczak W; Wlasiuk P; Kosior K; Piechnik A; Bojarska-Junak A; Dmoszynska A; Giannopoulos K
PLoS One; 2012; 7(4):e35178. PubMed ID: 22532845
[TBL] [Abstract][Full Text] [Related]
17. Bone marrow dendritic cells support the survival of chronic lymphocytic leukemia cells in a CD84 dependent manner.
Barak AF; Lewinsky H; Perpinial M; Huber V; Radomir L; Kramer MP; Sever L; Wolf Y; Shapiro M; Herishanu Y; Jung S; Becker-Herman S; Shachar I
Oncogene; 2020 Feb; 39(9):1997-2008. PubMed ID: 31772329
[TBL] [Abstract][Full Text] [Related]
18. Distinct immune signatures in chronic lymphocytic leukemia and Richter syndrome.
Wang Y; Sinha S; Wellik LE; Secreto CR; Rech KL; Call TG; Parikh SA; Kenderian SS; Muchtar E; Hayman SR; Koehler AB; Van Dyke DL; Leis JF; Slager SL; Dong H; Kay NE; He R; Ding W
Blood Cancer J; 2021 May; 11(5):86. PubMed ID: 33972504
[TBL] [Abstract][Full Text] [Related]
19. Depletion of CLL-associated patrolling monocytes and macrophages controls disease development and repairs immune dysfunction in vivo.
Hanna BS; McClanahan F; Yazdanparast H; Zaborsky N; Kalter V; Rößner PM; Benner A; Dürr C; Egle A; Gribben JG; Lichter P; Seiffert M
Leukemia; 2016 Mar; 30(3):570-9. PubMed ID: 26522085
[TBL] [Abstract][Full Text] [Related]
20. PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy.
Zamarin D; Ricca JM; Sadekova S; Oseledchyk A; Yu Y; Blumenschein WM; Wong J; Gigoux M; Merghoub T; Wolchok JD
J Clin Invest; 2018 Apr; 128(4):1413-1428. PubMed ID: 29504948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
